Tyler Van Buren
Stock Analyst at TD Cowen
(2.24)
# 2,683
Out of 4,749 analysts
57
Total ratings
43.48%
Success rate
-1.41%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $30.07 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $11.40 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $38.25 | +96.08% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $12.62 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $13.45 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $39.42 | +52.21% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $5.08 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $19.31 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $672.98 | +78.31% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $54.14 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $22.29 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $97.20 | -12.55% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $41.59 | -27.87% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.60 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $22.99 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $68.13 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.36 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.97 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $20.46 | +46.63% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.21 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.30 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $32.88 | +112.90% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.74 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.61 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.46 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.72 | +2,806.98% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $25.80 | +3,291.47% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $1.44 | +2,677.78% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $19.71 | +102.94% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $9.38 | +219.83% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.56 | +10,612.37% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $10.75 | +365.12% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.99 | +2,919.32% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $4.22 | +4,639.34% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.62 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.73 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $30.07
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $11.40
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $38.25
Upside: +96.08%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $12.62
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $13.45
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $39.42
Upside: +52.21%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $5.08
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $19.31
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $672.98
Upside: +78.31%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $54.14
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $22.29
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $97.20
Upside: -12.55%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $41.59
Upside: -27.87%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.60
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $22.99
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $68.13
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $41.36
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.97
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $20.46
Upside: +46.63%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $34.21
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.30
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $32.88
Upside: +112.90%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.74
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $17.61
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.46
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.72
Upside: +2,806.98%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $25.80
Upside: +3,291.47%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $1.44
Upside: +2,677.78%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $19.71
Upside: +102.94%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $9.38
Upside: +219.83%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.56
Upside: +10,612.37%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $10.75
Upside: +365.12%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.99
Upside: +2,919.32%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $4.22
Upside: +4,639.34%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $8.62
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $17.73
Upside: -